### Adjuvant Trials - [[SWOG 0809]] (2015): Prospective phase II study supporting adjuvant **gemcitabine + capecitabine + XRT** after resection of EHCC and gallbladder cancer, particularly for node-positive or margin-positive disease. - [[BILCAP]] (2019): Adjuvant **capecitabine** improved survival in per-protocol analysis and established the modern postoperative standard after BTC resection. --- ### Metastatic / Advanced Disease - [[ABC-02]] (2010): Established **gemcitabine/cisplatin** as first-line standard therapy for advanced BTC. - [[TOPAZ-1]] (2022): **Durvalumab** + **gemcitabine/cisplatin** improved survival and established chemoimmunotherapy as the modern first-line standard. - [[KEYNOTE-966]] (2023): **Pembrolizumab** + gemcitabine/cisplatin demonstrated an OS benefit, validating checkpoint inhibitor integration into frontline BTC therapy. - [[SWOG 1815]] (2023): **Gemcitabine/cisplatin/nab-paclitaxel (GAP)** failed to improve OS despite intensified cytotoxic therapy. --- ### Neoadjuvant / Perioperative / Conversion Therapy - [[NEO-GAP]] (2023): Neoadjuvant **gemcitabine/cisplatin/nab-paclitaxel (GAP)** established the feasibility and safety of neoadjuvant therapy in high-risk resectable ICC. - [[neoGOLP]] (2026): Combination chemotherapy, immunotherapy, and antiangiogenic therapy demonstrated promising conversion-to-resection rates in advanced ICC. --- ### Molecular & Targeted Therapy - [[ClarIDHy]] (2020): **Ivosidenib** improved progression-free survival in previously treated IDH1-mutated cholangiocarcinoma. - [[FIGHT-202]] (2020): **Pemigatinib** demonstrated meaningful activity in FGFR2 fusion-positive cholangiocarcinoma and helped establish precision oncology in BTC.